Home
>
National Drug Code (NDC)
>
RETROVIR
RETROVIR - 49702-211-20 - (zidovudine)
Drug Information of RETROVIR
| Product NDC: | 49702-211 |
| Proprietary Name: | RETROVIR |
| Non Proprietary Name: | zidovudine |
| Active Ingredient(s): | 100 mg/1 & nbsp; zidovudine |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of RETROVIR
| Product NDC: | 49702-211 |
| Labeler Name: | ViiV Healthcare Company |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA019655 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20101028 |
Package Information of RETROVIR
| Package NDC: | 49702-211-20 |
| Package Description: | 100 CAPSULE in 1 BOTTLE (49702-211-20) |
NDC Information of RETROVIR
| NDC Code | 49702-211-20 |
| Proprietary Name | RETROVIR |
| Package Description | 100 CAPSULE in 1 BOTTLE (49702-211-20) |
| Product NDC | 49702-211 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | zidovudine |
| Dosage Form Name | CAPSULE |
| Route Name | ORAL |
| Start Marketing Date | 20101028 |
| Marketing Category Name | NDA |
| Labeler Name | ViiV Healthcare Company |
| Substance Name | ZIDOVUDINE |
| Strength Number | 100 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
